PMID- 30831623
OWN - NLM
STAT- MEDLINE
DCOM- 20190411
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 40
IP  - 2
DP  - 2019 Feb 14
TI  - [Efficacy and safety of domestic dasatinib as second-line treatment for chronic 
      myeloid leukemia patients in the chronic phase].
PG  - 98-104
LID - 10.3760/cma.j.issn.0253-2727.2019.02.002 [doi]
AB  - Objective: To investigate the efficiency and safety of domestic tyrosine kinase 
      inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with 
      chronic myeloid leukemia in chronic phase (CML-CP). Methods: A retrospective 
      analysis of clinical data of CML-CP patients who received domestic dasatinib as 
      second-line treatment in the CML collaborative group hospitals of Hubei province 
      from March 2016 to July 2018 was performed. The optimal response rate, the 
      cumulative complete cytogenetic response (CCyR), the cumulative major molecular 
      responses (MMR), progression free survival (PFS), event free survival (EFS) and 
      adverse effects (AEs) of the patients were assessed at 3, 6 and 12 months of 
      treatment. Results: A total of 83 CML-CP patients were enrolled in this study. 
      The median follow-up time was 23 months. The optimal response rates at 3, 6 and 
      12 months in 83 CML-CP patients treated with dasatinib were 77.5% (54/71), 72.6% 
      (61/75) and 60.7% (51/69), respectively. By the end of follow-up, the cumulative 
      CCyR and MMR rates were 65.5% (55/80) and 57.1% (48/73), respectively. The median 
      time to achieving CCyR and MMR was 3 months. During follow-up time, the PFS rate 
      was 94.0% (79/83) and the EFS rate was 77.4% (65/83). The most common 
      non-hematological AEs of dasatinib were edema (32.5%), rash itching (18.1%) and 
      fatigue (13.3%). The common hematological AEs of dasatinib were thrombocytopenia 
      (31.3%), leukopenia (19.3%) and anemia (6.0%). Conclusion: Domestic dasatinib was 
      effective and safe as the second-line treatment of CML-CP patients and it can be 
      used as an option for CML-CP patients.
FAU - Chen, Y L
AU  - Chen YL
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Wang, L
AU  - Wang L
AD  - The First People's Hospital of Jingmen, Jingmen 448000, China.
FAU - Yan, G L
AU  - Yan GL
AD  - Xiangyang Central Hospital, Xiangyang 441021, China.
FAU - Yang, Z Z
AU  - Yang ZZ
AD  - Suizhou Central Hospital, Suizhou 441300, China.
FAU - Huang, Z P
AU  - Huang ZP
AD  - Jingzhou Central Hospital, Jingzhou 434020, China.
FAU - Zhang, Y S
AU  - Zhang YS
AD  - The First People's Hospital of Jingzhou, Jingzhou 434000, China.
FAU - Zhao, Z
AU  - Zhao Z
AD  - Min Da Hospital Affiliated to Hubei Institute for Nationalities, Enshi 445000, 
      China.
FAU - Wan, C C
AU  - Wan CC
AD  - Shiyan Taihe Hospital, Shiyan 442000, China.
FAU - Bao, Y
AU  - Bao Y
AD  - The First People's Hospital of Xiangyang, Xiangyang 441000, China.
FAU - Xiang, H
AU  - Xiang H
AD  - Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China.
FAU - Yin, H
AU  - Yin H
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Chen, L F
AU  - Chen LF
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Xiong, Y Y
AU  - Xiong YY
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Meng, L
AU  - Meng L
AD  - Tongji Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Li, W M
AU  - Li WM
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Antineoplastic Agents
MH  - Dasatinib/*therapeutic use
MH  - Humans
MH  - Imatinib Mesylate
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
MH  - Protein Kinase Inhibitors
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7342660
OTO - NOTNLM
OT  - Domestic dasatinib
OT  - Efficiency
OT  - Leukemia, myeloid, chronic
OT  - Safety
EDAT- 2019/03/05 06:00
MHDA- 2019/04/12 06:00
PMCR- 2019/02/01
CRDT- 2019/03/05 06:00
PHST- 2019/03/05 06:00 [entrez]
PHST- 2019/03/05 06:00 [pubmed]
PHST- 2019/04/12 06:00 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - cjh-40-02-098 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2019.02.002 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2019 Feb 14;40(2):98-104. doi: 
      10.3760/cma.j.issn.0253-2727.2019.02.002.